Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ:NTRA), recently reported transactions involving the company’s common stock. The company, now valued at $22.8 billion, has seen its stock surge 148% over the past year. On February 5, Fesko acquired 1,675 shares through the vesting of Restricted Stock Units (RSUs). These RSUs were granted on October 22, 2021, and vested upon meeting specific performance criteria.
The following day, February 6, Fesko sold 663 shares at a price of $177.77 each, totaling $117,861. This sale was conducted to cover tax obligations related to the RSU vesting. After these transactions, Fesko holds 156,044 shares of Natera. According to InvestingPro, the stock is trading near its 52-week high of $183, with strong momentum indicators and a "GOOD" overall financial health rating. Discover 13 additional key insights about Natera with an InvestingPro subscription, including detailed valuation metrics and growth forecasts.
In other recent news, Natera Inc . has made significant strides in various areas of its operations. Canaccord Genuity maintained its Buy rating on Natera, emphasizing the positive results from the company’s Signatera test in two major clinical colorectal cancer studies. Barclays (LON:BARC) also upgraded Natera’s stock rating to Overweight, citing its successful expansion into new markets, particularly in minimal residual disease (MRD) testing.
Natera is also involved in an expanded patent infringement lawsuit against NeoGenomics (NASDAQ:NEO) over the RaDaR assay. The company has added another patent to its initial complaint in the ongoing litigation. In addition, Natera recently amended its employment agreement with Executive Chairman Dr. Matthew Rabinowitz, adjusting his salary, annual cash bonus, and equity awards.
Despite the anticipation of new competition, TD Cowen reiterated its Buy rating on Natera shares, expressing confidence in the company’s continued growth. The firm highlighted the company’s positive stance on the prospects of Signatera and its expectations for sustained momentum in product volumes and pricing. These developments underscore Natera’s commitment to innovation and growth in the genetic testing field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.